Susquehanna Fundamental Investments LLC Takes $17.83 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Susquehanna Fundamental Investments LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 50,535 shares of the biotechnology company's stock, valued at approximately $17,831,000. Susquehanna Fundamental Investments LLC owned approximately 0.11% of United Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Nebula Research & Development LLC acquired a new stake in United Therapeutics during the 4th quarter valued at $1,617,000. Lord Abbett & CO. LLC grew its holdings in United Therapeutics by 7.4% during the 4th quarter. Lord Abbett & CO. LLC now owns 216,651 shares of the biotechnology company's stock valued at $76,443,000 after purchasing an additional 14,956 shares in the last quarter. Hancock Whitney Corp grew its holdings in United Therapeutics by 50.0% during the 4th quarter. Hancock Whitney Corp now owns 7,708 shares of the biotechnology company's stock valued at $2,720,000 after purchasing an additional 2,569 shares in the last quarter. Voya Investment Management LLC boosted its stake in United Therapeutics by 4.3% during the 4th quarter. Voya Investment Management LLC now owns 38,548 shares of the biotechnology company's stock valued at $13,601,000 after acquiring an additional 1,581 shares during the last quarter. Finally, Integrated Wealth Concepts LLC boosted its stake in United Therapeutics by 14.1% during the 4th quarter. Integrated Wealth Concepts LLC now owns 9,962 shares of the biotechnology company's stock valued at $3,515,000 after acquiring an additional 1,230 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the completion of the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This represents a 23.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Dwek sold 3,000 shares of the stock in a transaction on Monday, April 21st. The shares were sold at an average price of $285.57, for a total value of $856,710.00. Following the sale, the director now owns 1,750 shares of the company's stock, valued at $499,747.50. This trade represents a 63.16 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,500 shares of company stock worth $24,472,050 over the last ninety days. Company insiders own 11.90% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research analyst reports. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a research note on Monday, April 21st. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research note on Monday, April 21st. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright restated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. Finally, Wells Fargo & Company restated an "equal weight" rating and issued a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $390.17.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $4.25 during mid-day trading on Thursday, reaching $298.84. 170,136 shares of the company traded hands, compared to its average volume of 447,772. United Therapeutics Co. has a fifty-two week low of $236.65 and a fifty-two week high of $417.82. The firm has a market cap of $13.42 billion, a PE ratio of 13.12, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The stock has a fifty day simple moving average of $304.50 and a 200-day simple moving average of $345.39.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.17 earnings per share. As a group, analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.